Adlai Nortye has dosed the first patient in Australia in the global Phase I trial of AN4035 and received U.S. FDA clearance to expand the study. The milestone gives investors a defined clinical-development path for the company’s CEACAM5-targeting ADC, with full Phase Ia data targeted for the second half of 2027.

Key Highlights

  • AN4035 will be tested as a standalone treatment and alongside cetuximab in CEACAM5-enriched, RAS-addicted solid tumors.
  • Adlai Nortye is also filing an AN4035 IND application with China’s National Medical Products Administration.
  • The U.S. FDA issued a “Study-May-Proceed” letter for AN4035’s investigational new drug application.

Adlai Nortye Group Ltd. (NASDAQ: ANL) has dosed the first patient in Australia in the global Phase I trial of AN4035, its CEACAM5-targeting antibody-drug conjugate. The U.S. Food and Drug Administration has also issued a “Study-May-Proceed” letter for the investigational new drug application, clearing expansion of the study into the United States.

AN4035 Trial Evaluates Safety and Early Activity

Its measures include safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy. The company is also filing an investigational new drug application for AN4035 with China’s National Medical Products Administration. AN4035 uses a pan-RAS(ON) inhibitor payload attached to an antibody that targets CEACAM5. Adlai Nortye said the candidate is designed to deliver the payload selectively to tumors while reducing exposure to normal tissues.

Preclinical testing showed favorable thermal and plasma stability, along with desired pharmacokinetic properties. Compared with the payload alone, the ADC showed greater target-mediated tumor retention and improved tumor selectivity over normal tissues, which the company said resulted in a favorable therapeutic index.